Previous close | 10.28 |
Open | 10.27 |
Bid | 10.00 x 50000 |
Ask | 10.04 x 50000 |
Day's range | 10.19 - 10.27 |
52-week range | 9.41 - 27.92 |
Volume | |
Avg. volume | 591 |
Market cap | 1.365B |
Beta (5Y monthly) | 1.10 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.19 (1.83%) |
Ex-dividend date | 14 Jun 2024 |
1y target est | N/A |
Amidst a buoyant U.S. stock market, with the S&P 500 reaching an unprecedented high and dovish remarks from the Federal Reserve Chairman boosting investor sentiment, small-cap stocks are drawing attention for their potential value. In this environment, identifying undervalued small-cap companies with insider buying can signal opportunities for informed investors looking to diversify their portfolios.
Amidst a buoyant U.S. market landscape, marked by the S&P 500 reaching an unprecedented high and dovish remarks from Federal Reserve Chairman Jerome Powell, small-cap stocks present unique opportunities for discerning investors. In this context, understanding the intrinsic qualities that define undervalued small-cap stocks becomes crucial to identifying potential investment gems.
Despite a flat performance over the last week, the United States stock market has seen an impressive 24% increase over the past year with earnings expected to grow by 15% annually. In such a thriving environment, undervalued small-cap stocks like AtriCure, which show promising insider actions, could present intriguing opportunities for investors looking for potential growth.